Pioglitazone Mitigates Arsenic-Induced Cardiotoxicity via Lipid Metabolism: Network Pharmacology and Molecular Docking Approach

Key Points

• Cardiotoxicity is reduced with pioglitazone treatment, supporting its protective role against arsenic.
• An analysis of molecular docking shows significant interactions between pioglitazone and key lipid metabolism pathways.
• Network pharmacology highlights the complex interactions in the cardiotoxicity model involving arsenic exposure.
• Further validation in human models is necessary, as findings are based on molecular simulations and theoretical predictions.